Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Status: Enrolling
Updated:  11/7/2012
LSU Health Sciences Center
mi
from
Shreveport, LA
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Status: Enrolling
Updated: 11/7/2012
LSU Health Sciences Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Status: Enrolling
Updated:  11/7/2012
Bayshore Community Hospital
mi
from
Holmdel, NJ
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Status: Enrolling
Updated: 11/7/2012
Bayshore Community Hospital
mi
from
Holmdel, NJ
Click here to add this to my saved trials
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Status: Enrolling
Updated:  11/7/2012
Wound Institute & Research Center
mi
from
Dunmore, PA
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Status: Enrolling
Updated: 11/7/2012
Wound Institute & Research Center
mi
from
Dunmore, PA
Click here to add this to my saved trials
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Status: Enrolling
Updated:  11/7/2012
Lake Washington Vascular Surgeons
mi
from
Bellevue, WA
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers
Status: Enrolling
Updated: 11/7/2012
Lake Washington Vascular Surgeons
mi
from
Bellevue, WA
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
Huntsville, AL
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
Huntsville, AL
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
Tucson, AZ
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
Jonesboro, AR
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
Long Beach, CA
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
Hialeah, FL
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
Hialeah, FL
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
Anderson, IN
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
Anderson, IN
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
Kansas City, KA
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
Kansas City, KA
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
Monroe, LA
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
Monroe, LA
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
Boston, MA
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
Mexico, MO
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
Mexico, MO
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
Fayetteville, NC
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
Fayetteville, NC
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
Oklahoma City, OK
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
Portland, OR
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated:  11/12/2012
Tranzyme Investigational Site
mi
from
El Paso, TX
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Status: Enrolling
Updated: 11/12/2012
Tranzyme Investigational Site
mi
from
El Paso, TX
Click here to add this to my saved trials
Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment
An Open-label, Single Dose, Parallel-group Study to Evaluate the Pharmacokinetics of LCQ908 in Patients With Mild, Moderate and Severe Hepatic Impairment Compared to Age, Gender and Weight-matched Healthy Volunteers.
Status: Enrolling
Updated:  11/15/2012
Novartis Investigative Site
mi
from
Miami, FL
Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment
An Open-label, Single Dose, Parallel-group Study to Evaluate the Pharmacokinetics of LCQ908 in Patients With Mild, Moderate and Severe Hepatic Impairment Compared to Age, Gender and Weight-matched Healthy Volunteers.
Status: Enrolling
Updated: 11/15/2012
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Impact of Vitamin D Supplementation on Cardiometabolic Risk Factors [The Daily D Health Study]
The Impact of Vitamin D Supplementation on Cardiometabolic Risk Factors in Schoolchildren
Status: Enrolling
Updated:  11/21/2012
Tufts University
mi
from
Boston, MA
Impact of Vitamin D Supplementation on Cardiometabolic Risk Factors [The Daily D Health Study]
The Impact of Vitamin D Supplementation on Cardiometabolic Risk Factors in Schoolchildren
Status: Enrolling
Updated: 11/21/2012
Tufts University
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy of Quantum NPWT With Simultaneous Irrigation on Reduction of Wound Volume in Stage III/IV Pressure Ulcers.
A 12-week, Single Site, Randomized Controlled Trial to Compare the Efficacy of Quantum NPWT With and Without Simultaneous Irrigation Versus Standard of Care on Reduction of the Volume of Stage III/IV Pressure Ulcers.
Status: Enrolling
Updated:  11/27/2012
Henry Ford Hospital System
mi
from
Detroit, MI
Efficacy of Quantum NPWT With Simultaneous Irrigation on Reduction of Wound Volume in Stage III/IV Pressure Ulcers.
A 12-week, Single Site, Randomized Controlled Trial to Compare the Efficacy of Quantum NPWT With and Without Simultaneous Irrigation Versus Standard of Care on Reduction of the Volume of Stage III/IV Pressure Ulcers.
Status: Enrolling
Updated: 11/27/2012
Henry Ford Hospital System
mi
from
Detroit, MI
Click here to add this to my saved trials
Laparoscopic Versus Open Appendectomy? Let the Patient Decide
Laparoscopic Versus Open Appendectomy? Let the Patient Decide
Status: Enrolling
Updated:  11/27/2012
Primary Children's Hospital
mi
from
Salt Lake City, UT
Laparoscopic Versus Open Appendectomy? Let the Patient Decide
Laparoscopic Versus Open Appendectomy? Let the Patient Decide
Status: Enrolling
Updated: 11/27/2012
Primary Children's Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease
Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease
Status: Enrolling
Updated:  11/29/2012
Palmetto Health Children's Hospital
mi
from
Columbia, SC
Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease
Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease
Status: Enrolling
Updated: 11/29/2012
Palmetto Health Children's Hospital
mi
from
Columbia, SC
Click here to add this to my saved trials
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Status: Enrolling
Updated:  11/29/2012
M.D. Anderson Cancer Center
mi
from
Houston, TX
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Status: Enrolling
Updated: 11/29/2012
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Fecal Microbiota Transplantation for Ulcerative Colitis
Evaluation of Durability of Fecal Microbiota Transplantation in Patients With Mild to Moderate Ulcerative Colitis
Status: Enrolling
Updated:  12/3/2012
University of Washington
mi
from
Seattle, WA
Fecal Microbiota Transplantation for Ulcerative Colitis
Evaluation of Durability of Fecal Microbiota Transplantation in Patients With Mild to Moderate Ulcerative Colitis
Status: Enrolling
Updated: 12/3/2012
University of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
Status: Enrolling
Updated:  12/4/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
Status: Enrolling
Updated: 12/4/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
Status: Enrolling
Updated:  12/4/2012
University of Wake Forest Baptist Medical Center
mi
from
Winston Salem, NC
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
Status: Enrolling
Updated: 12/4/2012
University of Wake Forest Baptist Medical Center
mi
from
Winston Salem, NC
Click here to add this to my saved trials
Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease
Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease
Status: Enrolling
Updated:  12/5/2012
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease
Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease
Status: Enrolling
Updated: 12/5/2012
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
North Alabama Research Center, LLC
mi
from
Athens, AL
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
North Alabama Research Center, LLC
mi
from
Athens, AL
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Alliance Clinical Research
mi
from
Birmingham, AL
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Alliance Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Greystone Medical Research, LLC
mi
from
Birmingham, AL
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Greystone Medical Research, LLC
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Decatur Gastroenterology Associates
mi
from
Decatur, AL
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Decatur Gastroenterology Associates
mi
from
Decatur, AL
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Digestive Health Specialists of the Southeast
mi
from
Dothan, AL
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Digestive Health Specialists of the Southeast
mi
from
Dothan, AL
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
PrimeTeam
mi
from
Dothan, AL
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
PrimeTeam
mi
from
Dothan, AL
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Clinical Research Consultants, Inc.
mi
from
Hoover, AL
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Clinical Research Consultants, Inc.
mi
from
Hoover, AL
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Medical Affliated Research Center, Inc.
mi
from
Huntsville, AL
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Medical Affliated Research Center, Inc.
mi
from
Huntsville, AL
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Saadat Ansari MD LLC
mi
from
Huntsville, AL
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Saadat Ansari MD LLC
mi
from
Huntsville, AL
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Scottsboro Quick Care Clinic
mi
from
Scottsboro, AL
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Scottsboro Quick Care Clinic
mi
from
Scottsboro, AL
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Greater Arizona Gastroenterology Associates
mi
from
Casa Grande, AZ
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Greater Arizona Gastroenterology Associates
mi
from
Casa Grande, AZ
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Connect Clinical Research Center
mi
from
Chandler, AZ
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Connect Clinical Research Center
mi
from
Chandler, AZ
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Novara Clinical Research
mi
from
Phoenix, AZ
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Novara Clinical Research
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Digestive Health Research Unit
mi
from
Scottsdale, AZ
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Digestive Health Research Unit
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Genova Clinical Research
mi
from
Tucson, AZ
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Genova Clinical Research
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Adobe Clinical Research, LLC
mi
from
Tucson, AZ
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Adobe Clinical Research, LLC
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Acrc/Arizona Clinical Research Center, Inc.
mi
from
Tucson, AZ
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Acrc/Arizona Clinical Research Center, Inc.
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Visions Clinical Research - Tucson
mi
from
Tucson, AZ
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Visions Clinical Research - Tucson
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
W/C Clinical Research
mi
from
Tucson, AZ
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
W/C Clinical Research
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Lynn Institute of the Ozarks
mi
from
Little Rock, AR
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Lynn Institute of the Ozarks
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Preferred Research Partners, Inc.
mi
from
Little Rock, AR
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Preferred Research Partners, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated:  12/10/2012
Applied Research Center of Arkansas
mi
from
Little Rock, AR
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Status: Enrolling
Updated: 12/10/2012
Applied Research Center of Arkansas
mi
from
Little Rock, AR
Click here to add this to my saved trials